Table of Content - Pet Cancer Therapeutics Market

The pet cancer therapeutics include chemotherapy drugs, targeted therapies, combination therapies, and immunotherapy vaccines, which are commonly recommended by the veterinary doctors. The drugs are mostly recommended to treat various conditions such as lymphoma, mast cell tumors, fibrosarcoma, hemangiosarcoma, and others. Currently, a wide range of formulations are available in the global market for the treatment of pet cancers, which can be administered in the form of tablets, injections or can be applied topically. Thus, the large variety of treatment options has made it easy for the pets to receive effective cancer treatment suitable to curb the condition.

Market Dynamics

The major factor driving growth of the pet cancer therapeutics market include robust number of pipeline drugs for the treatment of highly prevalent conditions such as lymphoma and melanoma. For instance, in 2017, Aratana Therapeutics received approval from the United States Department of Agriculture (USDA) Center for Veterinary Biologics for canine osteosarcoma vaccine- AT-014 for the treatment of dogs diagnosed with osteosarcoma, one year of age or older. The drug candidate was licensed exclusively from Advaxis, Inc. and is currently in the pivotal trial. Moreover, the private and government organizations such as Veterinary Cancer Society, Petco Foundation, and Animal Cancer Foundation are working together to formulate novel drugs for dogs and cats, which is a major factor expected to propel growth of the pet cancer therapeutics market over the forecast period. However, lack of awareness regarding pet diseases, high cost, and adverse effects of the drugs are the factors restraining pet cancer therapeutics market growth.

Key features of the study:

This report provides in-depth analysis of pet cancer therapeutics market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2026 – 2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global pet cancer therapeutics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Aratana Therapeutics, Inc., AB Science, Boehringer Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc., VetDC, Inc., Karyopharm Therapeutics, Inc., Rhizen Pharmaceuticals SA, Regeneus Ltd., Oasmia Pharmaceuticals AB, and Zoetis
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global pet cancer therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pet cancer therapeutics market

Market Segmentation

By Therapy Type: (Revenue, USD Bn, 2021-2033)
- Chemotherapy
- Targeted Therapy
- Combination Therapy
- Immunotherapy
By Pet Type: (Revenue, USD Bn, 2021-2033)
- Cat
- Dog
- Horse
By Mode of Administration: (Revenue, USD Bn, 2021-2033)
- Oral
- Intravenous
- Topical
By Application: (Revenue, USD Bn, 2021-2033)
- Lymphoma
- Mast Cell Cancer
- Melanoma
- Mammary and Squamous Cell Cancer
- Others
By Region: (Revenue, USD Bn, 2021-2033)
- North America
  - U.S.
  - Canada
- Latin America
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- Europe
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - GCC
  - Israel
  - Rest of Middle East
- Africa
  - South Africa
  - Central Africa
  - North Africa
Key Players
- Aratana Therapeutics, Inc.
- AB Science
- Boehinger Ingelheim International GmbH
- Zenoaq
- Morphogenesis, Inc.
- VetDC, Inc.
- Karyopharm Therapeutics, Inc.
- Regeneus Ltd.
- Rhizen Pharmaceuticals SA
- Oasmia Pharmaceuticals AB
- Zoetis

Table of Contents

Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snippet, By Therapy Type
  - Market Snippet, By Pet Type
  - Market Snippet, By Mode of Administration
  - Market Snippet, By Application
  - Market Snippet, By Region
- Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
  - Drivers
  - Restraints
  - Market Opportunities
- Key Highlights
- Pipeline Analysis
- Regulatory Guidelines
- Initiatives for Prevention of Pet Cancer
- Approved Targeted Therapies for Pet Cancer
- Epidemiology
Global Pet Cancer Therapeutics Market, By Therapy Type, 2021-2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022-2033
  - Segment Trends
- Chemotherapy
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Targeted Therapy
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Combination Therapy
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Immunotherapy
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Global Pet Cancer Therapeutics Market, By Pet Type, 2021-2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022-2033
  - Segment Trends
- Cat
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Dog
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Horse
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Global Pet Cancer Therapeutics Market, By Mode of Administration, 2021-2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022-2033
  - Segment Trends
- Oral
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Intravenous
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Topical
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Global Pet Cancer Therapeutics Market, By Application, 2021-2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022-2033
  - Segment Trends
- Lymphoma
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Mast Cell Cancer
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Melanoma
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Mammary and Squamous Cell Cancer
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Global Pet Cancer Therapeutics Market, By Region, 2021-2033, (USD Bn)
- Introduction
  - Market Share Analysis, By Region, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, For Regions, 2022-2033
- North America
  - Market Size and Forecast, By Therapy Type, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Pet Type, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Mode of Administration, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Application, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Country, 2021-2033, (USD Bn)
    - U.S.
    - Canada
- Latin America
  - Market Size and Forecast, By Therapy Type, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Pet Type, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Mode of Administration, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Application, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Country, 2021-2033, (USD Bn)
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - Market Size and Forecast, By Therapy Type, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Pet Type, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Mode of Administration, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Application, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Country, 2021-2033, (USD Bn)
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - Market Size and Forecast, By Therapy Type, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Pet Type, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Mode of Administration, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Application, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Country, 2021-2033, (USD Bn)
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of APAC
- Middle East
  - Market Size and Forecast, By Therapy Type, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Pet Type, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Mode of Administration, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Application, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Country, 2021-2033, (USD Bn)
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - Market Size and Forecast, By Therapy Type, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Pet Type, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Mode of Administration, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Application, 2021-2033, (USD Bn)
  - Market Size and Forecast, By Country, 2021-2033, (USD Bn)
    - South Africa
    - Central Africa
    - North Africa
Competitive Landscape
- Heat Map Analysis
- Market Share Analysis (3x3 Matrix)
- Company Profiles
  - Aratana Therapeutics, Inc.
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Developments/Updates
    - Future Plans
  - AB Science
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Developments/Updates
    - Future Plans
  - Boehringer Ingelheim International GmbH
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Developments/Updates
    - Future Plans
  - Zenoaq
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Developments/Updates
    - Future Plans
  - Morphogenesis, Inc.
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Developments/Updates
    - Future Plans
  - VetDC, Inc.
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Developments/Updates
    - Future Plans
  - Karyopharm Therapeutics, Inc.
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Developments/Updates
    - Future Plans
  - Rhizen Pharmaceuticals SA
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Developments/Updates
    - Future Plans
  - Regeneus Ltd.
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Developments/Updates
    - Future Plans
  - Oasmia Pharmaceuticals AB
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Developments/Updates
    - Future Plans
  - Zoetis
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Developments/Updates
    - Future Plans
- Analyst Views
Section
- References
- Research Methodology
- About us and Sales Contact

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now

Credibility and Certifications

860519526

9001:2015

27001:2022

Need a Custom Report?

EXISTING CLIENTELE